Sagimet Biosciences Inc.
SGMTSagimet Biosciences Inc. in brief
Sagimet Biosciences Inc. is a listed company in the Biotechnology industry, based in Foster City, California, USA. Its market value was $744 M on 30 October 2026, which makes it the 10,758th largest listed company in the world and the 2,254th largest in the USA on this site. It employs about 16 people and David Happel is its chief executive. Its shares trade under the symbol SGMT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Sagimet Biosciences Inc.
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Our second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne.
The critical role of FASN overactivity in MASH makes it an attractive target for drug therapy. Our FASN inhibitor, denifanstat, targets multiple drivers of MASH by reducing steatosis, inflammation and fibrosis.
From the company's annual report filed with the US SEC: read the report
Sagimet Biosciences Inc. timeline
- 2007
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- ✎Renamed Sagimet Biosciences Inc.Formerly 3-V Biosciences, Inc..
- 2023
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 17 July 2023; shares registered for exchange trading on 11 July 2023.
Events of Sagimet Biosciences Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,071 (Jul 2023) · #3,578 (Jan 2024) · #1,753 (Mar 2026) · #2,365 (Aug 2026) · #2,397 (Oct 2026) · #2,256 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 6.7×
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -45.8%
- Liabilities / assets
- 4.4%
- R&D / revenue
- 989.0%
- Profit per employee
- $-3.2 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-57M | $-51M | — |
| Dec 2024 | — | — | $-54M | $-46M | — |
| Dec 2023 | $2M | — | $-31M | $-28M | -1394.0% |
| Dec 2022 | — | — | $-31M | $-31M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-46M | — | — | $-1.58 | — |
| Dec 2024 | $-42M | — | — | $-1.45 | — |
| Dec 2023 | $-24M | — | — | $-2.66 | — |
| Dec 2022 | $-24M | — | — | $-165.20 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-19M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 22, 20268-KCurrent reportRegulation FD disclosure
- Oct 1, 20268-KCurrent reportMaterial agreement
- Sep 30, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 13, 20268-KCurrent reportOther events
- Aug 11, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Jul 21, 20268-KCurrent reportRegulation FD disclosure
- Jun 12, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- Jun 3, 20268-KCurrent reportDirectors or officers changed
- May 12, 20268-KCurrent reportResults of operations
Official filings of Sagimet Biosciences Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-57 M
- Net income
- $-51 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $116 M
- Total liabilities
- $5 M
- Total equity
- $111 M
As of December-2025
Top 100 institutional investors in Sagimet Biosciences Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6,970,208 | +394,420 (+6.00%) | 9.77% | $69 M | Nov 13, 2026 |
| 2 | Balyasny Asset Management L.P. | 5,542,492 | +1,916,379 (+52.85%) | 7.77% | $55 M | Nov 16, 2026 |
| 3 | Silverarc Capital Management, LLC | 3,745,990 | +818,292 (+27.95%) | 5.25% | $37 M | Nov 12, 2026 |
| 4 | BVF Inc/il | 3,500,000 | +1,000,000 (+40.00%) | 4.90% | $35 M | Nov 16, 2026 |
| 5 | Woodline Partners LP | 3,143,952 | +143,300 (+4.78%) | 4.41% | $31 M | Nov 16, 2026 |
| 6 | Federated Hermes, Inc. | 3,093,603 | +1,006,888 (+48.25%) | 4.33% | $31 M | Nov 12, 2026 |
| 7 | Caligan Partners LP | 2,794,484 | +294,484 (+11.78%) | 3.92% | $28 M | Nov 16, 2026 |
| 8 | Commodore Capital LP | 2,757,742 | New | 3.86% | $27 M | Nov 16, 2026 |
| 9 | Vanguard Capital Management LLC | 2,626,548 | +60,276 (+2.35%) | 3.68% | $26 M | Nov 13, 2026 |
| 10 | Affinity Asset Advisors, LLC | 2,527,384 | +29,520 (+1.18%) | 3.54% | $25 M | Nov 13, 2026 |
| 11 | State Street Corp | 2,427,837 | +432,745 (+21.69%) | 3.40% | $24 M | Nov 12, 2026 |
| 12 | Saturn V Capital Management LP | 2,002,813 | +522,895 (+35.33%) | 2.81% | $20 M | Nov 16, 2026 |
| 13 | Great Point Partners LLC | 1,961,701 | -68,232 (-3.36%) | 2.75% | $19 M | Nov 16, 2026 |
| 14 | Ameriprise Financial Inc | 1,900,603 | +1,319,386 (+227.00%) | 2.66% | $19 M | Nov 16, 2026 |
| 15 | Ra Capital Management, L.P. | 1,800,000 | New | 2.52% | $18 M | Nov 16, 2026 |
| 16 | Geode Capital Management, LLC | 1,543,687 | +99,668 (+6.90%) | 2.16% | $15 M | Nov 6, 2026 |
| 17 | Aberdeen Group plc | 1,475,078 | +627,378 (+74.01%) | 2.07% | $15 M | Nov 10, 2026 |
| 18 | Spruce Street Capital LP | 1,400,000 | New | 1.96% | $14 M | Nov 13, 2026 |
| 19 | Blue Owl Capital Holdings LP | 1,125,544 | -135,000 (-10.71%) | 1.58% | $11 M | Nov 13, 2026 |
| 20 | Adage Capital Partners GP, L.L.C. | 1,111,200 | New | 1.56% | $11 M | Nov 16, 2026 |
| 21 | D. E. Shaw & Co., Inc. | 1,037,706 | +1,015,529 (+4579.20%) | 1.45% | $10 M | Nov 16, 2026 |
| 22 | Marshall Wace, LLP | 752,365 | New | 1.05% | $7 M | Nov 13, 2026 |
| 23 | Driehaus Capital Management LLC | 727,150 | +560,483 (+336.29%) | 1.02% | $7 M | Nov 16, 2026 |
| 24 | Atom Investors LP | 725,924 | +379,906 (+109.79%) | 1.02% | $7 M | Nov 16, 2026 |
| 25 | Goldman Sachs Group Inc | 568,526 | -190,560 (-25.10%) | 0.80% | $6 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Dimensional Fund Advisors LP | 527,478 | +129,506 (+32.54%) | 0.74% | $5 M | Nov 4, 2026 |
| 27 | Boothbay Fund Management, LLC | 518,764 | +54,669 (+11.78%) | 0.73% | $5 M | Nov 16, 2026 |
| 28 | J. Goldman & Co LP | 508,402 | New | 0.71% | $5 M | Nov 16, 2026 |
| 29 | Jones Hill Capital LP | 502,587 | New | 0.70% | $5 M | Nov 13, 2026 |
| 30 | Vanguard Portfolio Management LLC | 495,817 | +92,335 (+22.88%) | 0.69% | $5 M | Nov 13, 2026 |
| 31 | Northern Trust Corp | 482,434 | +14,049 (+3.00%) | 0.68% | $5 M | Nov 16, 2026 |
| 32 | Nantahala Capital Management, LLC | 471,831 | New | 0.66% | $5 M | Nov 13, 2026 |
| 33 | UBS Group AG | 440,911 | +100,981 (+29.71%) | 0.62% | $4 M | Nov 10, 2026 |
| 34 | Seven Fleet Capital Management LP | 429,113 | +25,568 (+6.34%) | 0.60% | $4 M | Nov 16, 2026 |
| 35 | Vanguard Fiduciary Trust Co | 425,613 | +24,775 (+6.18%) | 0.60% | $4 M | Nov 13, 2026 |
| 36 | Superstring Capital Management LP | 423,006 | New | 0.59% | $4 M | Nov 16, 2026 |
| 37 | Millennium Management LLC | 406,857 | -530,168 (-56.58%) | 0.57% | $4 M | Nov 16, 2026 |
| 38 | Farallon Capital Management, L.L.C. | 400,000 | -15,000 (-3.61%) | 0.56% | $4 M | Nov 16, 2026 |
| 39 | Morgan Stanley | 341,663 | +239,436 (+234.22%) | 0.48% | $3 M | Nov 13, 2026 |
| 40 | Raymond James Financial Inc | 338,821 | +6,798 (+2.05%) | 0.47% | $3 M | Nov 12, 2026 |
| 41 | Bank Of America Corp /de/ | 321,139 | +177,455 (+123.50%) | 0.45% | $3 M | Nov 16, 2026 |
| 42 | Rock Springs Capital Management LP | 315,458 | +65,458 (+26.18%) | 0.44% | $3 M | Nov 16, 2026 |
| 43 | Walleye Capital LLC | 307,785 | New | 0.43% | $3 M | Nov 13, 2026 |
| 44 | AWM Investment Company, Inc. | 300,000 | +220,000 (+275.00%) | 0.42% | $3 M | Nov 13, 2026 |
| 45 | BNP Paribas Financial Markets | 258,125 | +138,089 (+115.04%) | 0.36% | $3 M | Nov 12, 2026 |
| 46 | Palo Alto Investors LP | 250,000 | 0 (0.00%) | 0.35% | $2 M | Nov 16, 2026 |
| 47 | Bank of New York Mellon Corp | 210,523 | +9,875 (+4.92%) | 0.29% | $2 M | Nov 5, 2026 |
| 48 | Wellington Management Group LLP | 205,892 | +165,092 (+404.64%) | 0.29% | $2 M | Nov 16, 2026 |
| 49 | Barclays PLC | 202,396 | -25,535 (-11.20%) | 0.28% | $2 M | Nov 6, 2026 |
| 50 | Acadian Asset Management LLC | 186,004 | New | 0.26% | $2 M | Nov 9, 2026 |
| 51 | Charles Schwab Investment Management Inc | 175,873 | +1 (0.00%) | 0.25% | $2 M | Nov 16, 2026 |
| 52 | Invesco Ltd. | 172,355 | +137,624 (+396.26%) | 0.24% | $2 M | Nov 12, 2026 |
| 53 | XTX Topco Ltd | 166,874 | New | 0.23% | $2 M | Nov 16, 2026 |
| 54 | Sofinnova Investments, Inc. | 162,380 | -4,287 (-2.57%) | 0.23% | $2 M | Nov 16, 2026 |
| 55 | Nuveen, LLC | 134,413 | -6,224 (-4.43%) | 0.19% | $1 M | Nov 10, 2026 |
| 56 | Citadel Advisors LLC | 133,079 | +28,446 (+27.19%) | 0.19% | $1 M | Nov 16, 2026 |
| 57 | Caption Management, LLC | 110,898 | New | 0.16% | $1 M | Nov 16, 2026 |
| 58 | FNY Investment Advisers, LLC | 109,350 | +100 (+0.09%) | 0.15% | $1 M | Oct 16, 2026 |
| 59 | Susquehanna International Group, LLP | 100,018 | +89,068 (+813.41%) | 0.14% | $1 M | Nov 16, 2026 |
| 60 | Prelude Capital Management, LLC | 97,000 | New | 0.14% | $1 M | Nov 16, 2026 |
| 61 | RB Capital Management, LLC | 97,000 | 0 (0.00%) | 0.14% | $1 M | Nov 17, 2026 |
| 62 | Renaissance Technologies LLC | 89,700 | -257,227 (-74.14%) | 0.13% | $1 M | Nov 12, 2026 |
| 63 | Rhumbline Advisers | 72,274 | -2,065 (-2.78%) | 0.10% | $1 M | Nov 10, 2026 |
| 64 | Perceptive Advisors LLC | 67,674 | New | 0.09% | $1 M | Nov 16, 2026 |
| 65 | Kestra Advisory Services, LLC | 66,414 | 0 (0.00%) | 0.09% | $1 M | Nov 2, 2026 |
| 66 | Inspire Investing, LLC | 62,477 | New | 0.09% | $1 M | Oct 22, 2026 |
| 67 | ACT Capital Partners, L.P. | 60,000 | — | 0.08% | $1 M | Nov 6, 2026 |
| 68 | Rafferty Asset Management, LLC | 54,836 | +27,510 (+100.67%) | 0.08% | $1 M | Nov 13, 2026 |
| 69 | Persistent Asset Partners Ltd | 52,677 | +42,308 (+408.02%) | 0.07% | $1 M | Nov 13, 2026 |
| 70 | Deutsche Bank AG\ | 51,016 | -7,186 (-12.35%) | 0.07% | $1 M | Nov 6, 2026 |
| 71 | Hudson Bay Capital Management LP | 49,783 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 72 | Price T Rowe Associates Inc /MD/ | 48,883 | 0 (0.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 73 | Two Sigma Investments, LP | 47,502 | -34,400 (-42.00%) | 0.07% | $0 M | Nov 16, 2026 |
| 74 | Trexquant Investment LP | 42,802 | New | 0.06% | $0 M | Nov 16, 2026 |
| 75 | Vanguard Global Advisers, LLC | 38,369 | +16,611 (+76.34%) | 0.05% | $0 M | Nov 13, 2026 |
| 76 | Bridgeway Capital Management, LLC | 37,337 | -184,204 (-83.15%) | 0.05% | $0 M | Nov 16, 2026 |
| 77 | Jpmorgan Chase & Co | 35,874 | +6,944 (+24.00%) | 0.05% | $0 M | Nov 12, 2026 |
| 78 | MetLife Investment Management, LLC | 35,682 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 79 | Point72 Asset Management, L.P. | 35,629 | New | 0.05% | $0 M | Nov 16, 2026 |
| 80 | Empowered Funds, LLC | 33,237 | New | 0.05% | $0 M | Nov 13, 2026 |
| 81 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 32,299 | +2,182 (+7.25%) | 0.05% | $0 M | Nov 16, 2026 |
| 82 | HRT Financial LP | 31,614 | New | 0.04% | $0 M | Nov 13, 2026 |
| 83 | Gsa Capital Partners LLP | 30,453 | New | 0.04% | $0 M | Nov 16, 2026 |
| 84 | Wells Fargo & Company/mn | 26,308 | -37,688 (-58.89%) | 0.04% | $0 M | Nov 16, 2026 |
| 85 | Los Angeles Capital Management LLC | 25,687 | New | 0.04% | $0 M | Nov 12, 2026 |
| 86 | Citigroup Inc | 25,376 | -27,463 (-51.97%) | 0.04% | $0 M | Nov 4, 2026 |
| 87 | Connective Capital Management, LLC | 25,000 | New | 0.04% | $0 M | Nov 16, 2026 |
| 88 | Quantinno Capital Management LP | 24,453 | New | 0.03% | $0 M | Nov 13, 2026 |
| 89 | Alliancebernstein L.P. | 23,360 | +5,160 (+28.35%) | 0.03% | $0 M | Nov 16, 2026 |
| 90 | Cresset Asset Management, LLC | 23,079 | +3,000 (+14.94%) | 0.03% | $0 M | Nov 16, 2026 |
| 91 | Squarepoint Ops LLC | 22,441 | New | 0.03% | $0 M | Nov 9, 2026 |
| 92 | LPL Financial LLC | 21,920 | -4,830 (-18.06%) | 0.03% | $0 M | Nov 6, 2026 |
| 93 | Composition Wealth, LLC | 21,376 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 94 | SummitTX Capital, L.P. | 20,159 | -2,553 (-11.24%) | 0.03% | $0 M | Nov 16, 2026 |
| 95 | WINTON GROUP Ltd | 20,000 | New | 0.03% | $0 M | Nov 12, 2026 |
| 96 | Profund Advisors LLC | 19,737 | +5,234 (+36.09%) | 0.03% | $0 M | Oct 29, 2026 |
| 97 | Entropy Technologies, LP | 18,426 | New | 0.03% | $0 M | Nov 13, 2026 |
| 98 | Abacus Planning Group, Inc. | 18,064 | 0 (0.00%) | 0.03% | $0 M | Nov 2, 2026 |
| 99 | SEI Investments Co | 17,711 | +2,834 (+19.05%) | 0.02% | $0 M | Nov 10, 2026 |
| 100 | RPG Investment Advisory, LLC | 17,350 | 0 (0.00%) | 0.02% | $0 M | Oct 21, 2026 |
Mutual funds holding Sagimet Biosciences Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company | 2.08 M | $15 M | 2.3% | 0.52% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.86 M | $14 M | 2.0% | <0.01% | +139% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.50 M | $12 M | 1.6% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 983,147 | $8 M | 1.1% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 abrdn Life Sciences Investorsabrdn Inc. | 847,700 | $7 M | 0.93% | 0.95% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 659,000 | $5 M | 0.72% | <0.01% | +127% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 643,413 | $5 M | 0.70% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC | 585,181 | $4 M | 0.64% | 0.07% | new | May 29, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 431,516 | $3 M | 0.47% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 413,328 | $3 M | 0.45% | 0.04% | +118% | Jun 30, 2026 |
| 🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC | 301,060 | $2 M | 0.33% | 0.22% | +37% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 290,427 | $2 M | 0.32% | <0.01% | +104% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 197,472 | $2 M | 0.22% | 0.10% | +168% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 142,839 | $1 M | 0.16% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 136,754 | $1 M | 0.15% | <0.01% | +30% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 118,725 | $1 M | 0.13% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 109,843 | $1 M | 0.12% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 105,610 | $1 M | 0.12% | <0.01% | +125% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 101,803 | $1 M | 0.11% | <0.01% | +38% | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 85,272 | $1 M | 0.09% | <0.01% | +123% | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 78,077 | $1 M | 0.09% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 73,083 | $1 M | 0.08% | 0.02% | +27% | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 63,627 | $0 M | 0.07% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 67,035 | $0 M | 0.07% | <0.01% | +93% | Jul 31, 2026 |
| 🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC | 52,449 | $0 M | 0.06% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 48,900 | $0 M | 0.05% | 0.26% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 47,683 | $0 M | 0.05% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 43,060 | $0 M | 0.05% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 42,600 | $0 M | 0.05% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC | 34,976 | $0 M | 0.04% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 33,403 | $0 M | 0.04% | 0.05% | new | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 30,398 | $0 M | 0.03% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 33,033 | $0 M | 0.04% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 32,776 | $0 M | 0.04% | <0.01% | +137% | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 26,856 | $0 M | 0.03% | <0.01% | +88% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 27,951 | $0 M | 0.03% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 23,336 | $0 M | 0.03% | <0.01% | +83% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 20,225 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 19,417 | $0 M | 0.02% | <0.01% | +25% | Jun 30, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 21,062 | $0 M | 0.02% | <0.01% | +126% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 17,984 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 18,571 | $0 M | 0.02% | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 16,793 | $0 M | 0.02% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 15,100 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 13,175 | $0 M | 0.01% | 0.05% | +148% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 13,049 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 12,962 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 12,099 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 10,422 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 9,220 | $0 M | 0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 9,100 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 9,100 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 8,962 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 8,901 | $0 M | <0.01% | 0.01% | +116% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 8,721 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 7,916 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 7,018 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 6,911 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 6,881 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 6,764 | $0 M | <0.01% | <0.01% | +127% | Jul 31, 2026 |
| 🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC | 6,156 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 5,333 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 5,196 | $0 M | <0.01% | 0.01% | new | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 4,699 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 4,643 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 4,167 | $0 M | <0.01% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 4,056 | $0 M | <0.01% | 0.01% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 4,236 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 3,763 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 3,964 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 3,410 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 3,445 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 3,012 | $0 M | <0.01% | 0.02% | no change | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 2,628 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 2,817 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 2,492 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP | 2,377 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,060 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 2,020 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 1,947 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 1,776 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,483 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 1,172 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 1,048 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC | 662 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 606 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 550 | $0 M | <0.01% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc. | 488 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 327 | $0 M | <0.01% | <0.01% | +122% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 89 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Sagimet Biosciences Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | George KembleDirector | Option exercise10b5-1 plan | +326,618 | $6.360 | $2.1 M | 388,779 | Form 4 |
| filed | George KembleDirector | Option exercise10b5-1 plan | +24,369 | $6.360 | $155 K | 413,148 | Form 4 |
| filed | George KembleDirector | Sell10b5-1 plan | -350,987 | $10.23 | $3.6 M | 62,161 | Form 4 |
| filed | George KembleDirector | Option exercise10b5-1 plan | +9,751 | $6.360 | $62 K | 71,912 | Form 4 |
| filed | George KembleDirector | Option exercise10b5-1 plan | +10,455 | $6.360 | $66 K | 82,367 | Form 4 |
| filed | George KembleDirector | Sell10b5-1 plan | -20,206 | $9.950 | $201 K | 62,161 | Form 4 |
| filed | David HappelPresident & CEO, Director | Sell | -64,051 | $7.760 | $497 K | 741,570 | Form 4 |
| filed | George KembleDirector | Sell10b5-1 plan | -18,844 | $7.460 | $141 K | 62,161 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Sagimet Biosciences Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-79.48 reverse split
Trading halts
- 2025-01-06 14:30 UTC, code LUDP, resumed 14:40 UTC
Fails to deliver
- : 201 shares at $10.43
- : 717 shares at $9.58
- : 100 shares at $9.95
- : 24,904 shares at $9.74
- : 4,606 shares at $8.02
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Sagimet Biosciences Inc. scorecard#
Passes 1 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median6.7×Price to book 6.7× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.58 vs -1.45Diluted EPS -1.58 in fiscal 2025 against -1.45 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$51 MNet income -$51 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-38.2%-38.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities22.8×Current ratio 22.82 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year3.2%Diluted shares up 3.2% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Sagimet Biosciences Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | 2.0—100% | — | |
| Research and development | 39+1.6%— | 38+94.4%— | 20−20.6%989% | 25—— | |
| General and administrative | 18+11.4%— | 16+23.5%— | 13+111%648% | 6.1—— | |
| Operating expenses | 57+4.5%— | 54+66.3%— | 33+5.4%1637% | 31—— | |
| Operating income | −57—— | −54—— | −31—−1537% | −31—— | |
| Other non-operating income (expense) | 5.9−34.2%— | 8.9+210%— | 2.9+415%143% | 0.6—— | |
| Income tax | 0—— | 0—— | — | — | |
| Net income attributable to shareholders | −51—— | −46—— | −28—−1394% | −30—— | |
| Earnings per share, basic | -1.58—— | -1.45—— | -2.66—— | -165.20—— | |
| Earnings per share, diluted | -1.58—— | -1.45—— | -2.66—— | -165.20—— | |
| Shares, weighted average (basic) | 32+3.2%— | 31+200%— | 10+5566%— | 0.2—— | |
| Shares, weighted average (diluted) | 32+3.2%— | 31+200%— | 10+5566%— | 0.2—— | |
| Balance sheet | |||||
| Cash and cash equivalents | 35−53.8%30.1% | 76+0.9%47.3% | 75+47456%77.7% | 0.2r0.2—0.5% | |
| Short-term investments | 78+3.6%67.1% | 75+282%47.1% | 20−38.6%20.4% | 32—97.4% | |
| Other current assets | 0.2+26.8%0.2% | 0.2+112%0.1% | 0.1+118%0.1% | 0.0r0.1—0.1% | |
| Current assets | 116−23.8%99.9% | 153+58.1%95.3% | 97+195%99.9% | 33—99.3% | |
| Right-of-use (leased) assets | 0.1+1.3%0.1% | 0.1+5.5%0.0% | 0.1−65.6%0.1% | 0.2—0.6% | |
| Total assets | 116−27.3%100% | 160+65.7%100% | 97+193%100% | 33—100% | |
| Accounts payable | 1.3−8.1%1.1% | 1.4+666%0.9% | 0.2−83.5%0.2% | 1.1—3.4% | |
| Current liabilities | 5.1+14.5%4.4% | 4.5−21.2%2.8% | 5.7+7.1%5.8% | 5.3—16.0% | |
| Lease liabilities (non-current) | 0—0.0% | — | — | 0.1—0.2% | |
| Total liabilities | 5.1+14.5%4.4% | 4.5−21.2%2.8% | 5.7+5.5%5.8% | 5.4—16.2% | |
| Retained earnings | −346—−297% | −295—−184% | −250—−258% | −222—−672% | |
| Shareholders' equity | 111−28.5%95.6% | 156+71.1%97.2% | 91—94.2% | −187—−566% | |
| Total liabilities and equity | 116−27.3%100% | 160+65.7%100% | 97+193%100% | 33—100% | |
| Shares outstanding | — | — | — | 0.2—— | |
| Cash-flow statement | |||||
| Share-based compensation | 6.4+22.0%— | 5.3+6.0%— | 5.0+165%250% | 1.9—— | |
| Cash from operating activities | −46—— | −42—— | −24—−1188% | −24—— | |
| Cash from investing activities | 4.6—— | −62−590%— | 13—629% | −32—— | |
| Shares issued | 0−100%— | 106—— | — | — | |
| Cash from financing activities | 0.3−99.7%— | 105+21.6%— | 86—4308% | −0.1—— | |
| Report | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 0*—— | |
| Research and development | 42−10.6%— | 16+67.9%— | 12+59.1%— | 7.0−54.4%— | 6.7*−52.6%— | 9.7−23.1%— | 7.2+14.8%— | 15+192%— | 14*+151%— | 13—— | 6.3—— | 5.3—— | 5.7*—— | |
| General and administrative | 18+2.7%— | 5.2+13.5%— | 4.3−8.4%— | 4.7+4.3%— | 4.0*+1.3%— | 4.6+8.4%— | 4.7+9.4%— | 4.5+29.0%— | 4.0*+4.4%— | 4.2—— | 4.3—— | 3.5—— | 3.8*—— | |
| Operating expenses | 60−6.9%— | 22+50.5%— | 16+32.6%— | 12−41.0%— | 11*−40.8%— | 14−15.2%— | 12+12.6%— | 20+127%— | 18*+92.2%— | 17—— | 11—— | 8.8—— | 9.5*—— | |
| Operating income | −60—— | −22—— | −16—— | −12—— | −11*—— | −14—— | −12—— | −20—— | −18*—— | −17—— | −11—— | −8.8—— | −9.5*—— | |
| Other non-operating income (expense) | 6.5−1.6%— | 2.4+69.6%— | 1.9+21.2%— | 1.1−37.1%— | 1.2*−40.0%— | 1.4−37.5%— | 1.5−37.7%— | 1.7−21.0%— | 2.0*+51.6%— | 2.3—— | 2.5—— | 2.1—— | 1.3*—— | |
| Net income attributable to shareholders | −53—— | −19—— | −14—— | −11—— | −9.6*—— | −13—— | −10—— | −18—— | −16*—— | −15—— | −8.1—— | −6.6—— | −8.2*—— | |
| Earnings per share, basic | — | -0.31—— | -0.26—— | -0.33—— | — | -0.40—— | -0.32—— | -0.56—— | — | -0.45—— | -0.25—— | -0.23—— | — | |
| Earnings per share, diluted | — | -0.31—— | -0.26—— | -0.33—— | — | -0.40—— | -0.32—— | -0.56—— | — | -0.45—— | -0.25—— | -0.23—— | — | |
| Shares, weighted average (basic) | 62+92.0%— | 62+92.0%— | 53+65.0%— | 33+1.1%— | — | 32+1.0%— | 32+0.9%— | 32+10.9%— | — | 32—— | 32—— | 29—— | — | |
| Shares, weighted average (diluted) | 62+92.0%— | 62+92.0%— | 53+65.0%— | 33+1.1%— | — | 32+1.0%— | 32+0.9%— | 32+10.9%— | — | 32—— | 32—— | 29—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 111—39.3% | 111+241%39.3% | 166+292%63.0% | 37−43.4%34.0% | 35−53.8%30.1% | 32−57.8%25.3% | 42−55.9%30.8% | 65−63.4%44.3% | 76+0.9%47.3% | 77—44.1% | 96—50.8% | 177—90.9% | 75—77.7% | |
| Short-term investments | 125—44.5% | 125+49.0%44.5% | 74−10.6%28.2% | 68−15.0%63.0% | 78+3.6%67.1% | 84+11.6%65.6% | 83+18.0%60.5% | 80+372%54.6% | 75+282%47.1% | 75—43.2% | 70—37.3% | 17—8.7% | 20—20.4% | |
| Other current assets | 0.3—0.1% | 0.3+19.4%0.1% | 0.2+30.6%0.1% | 0.2−5.7%0.2% | 0.2+26.8%0.2% | 0.3+150%0.2% | 0.2+33.1%0.1% | 0.3+144%0.2% | 0.2+112%0.1% | 0.1—0.1% | 0.1—0.1% | 0.1—0.1% | 0.1—0.1% | |
| Current assets | 241—85.3% | 241+101%85.3% | 244+91.8%92.6% | 108−26.3%100.0% | 116−23.8%99.9% | 119−24.0%93.1% | 127−23.7%92.6% | 146−24.9%99.9% | 153+58.1%95.3% | 157—89.9% | 167—88.2% | 194—100.0% | 97—99.9% | |
| Right-of-use (leased) assets | 1.9—0.7% | 1.9+1543%0.7% | 2.0+1184%0.7% | 0.0+2.6%0.0% | 0.1+1.3%0.1% | 0.1+0.9%0.1% | 0.2+0.7%0.1% | 0.0+2.7%0.0% | 0.1+5.5%0.0% | 0.1—0.1% | 0.2—0.1% | 0.0—0.0% | 0.1—0.1% | |
| Total assets | 282—100% | 282+120%100% | 263+91.7%100% | 108−26.3%100% | 116−27.3%100% | 128−26.5%100% | 137−27.3%100% | 146−24.9%100% | 160+65.7%100% | 175—100% | 189—100% | 195—100% | 97—100% | |
| Accounts payable | 1.8—0.6% | 1.8−57.3%0.6% | 1.1−41.1%0.4% | 2.3−28.5%2.1% | 1.3−8.1%1.1% | 4.2+268%3.3% | 1.9−3.7%1.4% | 3.2+507%2.2% | 1.4+666%0.9% | 1.2—0.7% | 2.0—1.1% | 0.5—0.3% | 0.2—0.2% | |
| Current liabilities | 38—13.5% | 38+315%13.5% | 5.4−25.2%2.1% | 5.3—4.9% | 5.1+14.5%4.4% | 9.1—7.1% | 7.2—5.3% | — | 4.5−21.2%2.8% | — | — | — | 5.7—5.8% | |
| Lease liabilities (non-current) | 1.9—0.7% | 1.9—0.7% | 1.9—0.7% | — | 0—0.0% | — | — | — | — | — | — | — | — | |
| Total liabilities | 40—14.1% | 40—14.1% | 7.3—2.8% | — | 5.1+14.5%4.4% | — | — | 7.2+59.2%4.9% | 4.5−21.2%2.8% | 4.1—2.3% | 5.7—3.0% | 4.5—2.3% | 5.7—5.8% | |
| Retained earnings | −390—−138% | −390—−138% | −371—−141% | −357—−331% | −346—−297% | −337—−262% | −324—−236% | −313—−214% | −295—−184% | −279—−160% | −264—−140% | −256—−132% | −250—−258% | |
| Shareholders' equity | 242—85.9% | 242+103%85.9% | 256+96.8%97.2% | 102−26.3%95.1% | 111−28.5%95.6% | 119−30.1%92.9% | 130−29.0%94.7% | 139−26.9%95.1% | 156+71.1%97.2% | 171—97.7% | 183—97.0% | 190—97.7% | 91—94.2% | |
| Total liabilities and equity | 282—100% | 282+120%100% | 263+91.7%100% | 108−26.3%100% | 116−27.3%100% | 128−26.5%100% | 137−27.3%100% | 146−24.9%100% | 160+65.7%100% | 175—100% | 189—100% | 195—100% | 97—100% | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 9.6+52.7%— | 2.4+41.5%— | 3.7+131%— | 1.8+24.9%— | 1.7*+10.2%— | 1.7+9.2%— | 1.6+10.3%— | 1.5+93.9%— | 1.5*+17.0%— | 1.5—— | 1.4—— | 0.8—— | 1.3*—— | |
| Cash from operating activities | −44—— | −12*—— | −11*—— | −8.6—— | −12*—— | −10*—— | −9.1*—— | −15—— | −11*—— | −20*—— | −5.6*—— | −6.2—— | −7.1*—— | |
| Cash from investing activities | −73−151548%— | −73*−97765%— | −24*—— | 10+199%— | 14*+45.8%— | 0.1*−88.0%— | −13*—— | 3.4+13.8%— | 9.9*—— | 0.6*—— | −75*—— | 3.0—— | −20*—— | |
| Shares issued | — | 0*—— | — | — | 0*—— | 0*—— | — | — | 0*—— | 0*—— | 0*—— | 106—— | — | |
| Cash from financing activities | — | 30*+11004%— | — | — | 0*—— | 0.3*—— | — | — | 0*—— | 0*—— | −0.0*—— | 105—— | 0*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Sagimet Biosciences Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 5 · Material agreement 3 · Agreement ended 1 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
7 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2020 | $69 M | No. 7 | $50 to $250 million | 13 | equity | SEC |
| Feb 2019 | $35 M | No. 6 | $10 to $50 million | 19 | equity | SEC |
| Jun 2016 | $5 M | No. 5 | $2 to $10 million | 7 | equity, debt | SEC |
| Oct 2014 | $14 M | No. 4 | $10 to $50 million | 12 | equity | SEC |
| Jun 2013 | $8 M | No. 3 | $2 to $10 million | 2 | equity, options | SEC |
| Nov 2011 | $20 M | No. 2 | $10 to $50 million | 3 | equity, options | SEC |
| Jul 2009 | $15 M | No. 1 | $10 to $50 million | 4 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Discuss Sagimet Biosciences Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
Sagimet Biosciences Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $19 million.
- Mutual funds: 89 funds hold $96 millionautomatic update · Jul 31, 2026
89 mutual funds in 1 country hold shares of Sagimet Biosciences Inc. worth $96 million, about 13.9% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 76 funds added shares and 0 sold; on balance they bought $64 million. Share splits are not counted as trading.
How Sagimet Biosciences Inc. compares in Biotechnology
- Market cap$744 M · higher than 63% of 726
- Price / book6.7× · lower than 24% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Sagimet Biosciences Inc.🇺🇸 | $744 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Cybin D/B/A Helus Pharma$743 M
- Guizhou Sanli Pharmaceutical Co., Ltd$747 M
- Bright Minds Biosciences Inc.$750 M
- Valneva SE$759 M
- Alphamab Oncology$767 M
- Apnimed, Inc.$722 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Sagimet Biosciences Inc.? Verify and update this profile — free
Show Sagimet Biosciences Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.